US FDA panel to discuss cell-based flu vaccine research
This article was originally published in Scrip
Executive Summary
The US FDA's vaccines and related biological products advisory panel will meet on September 25th to hear presentations and discuss the use of Madin-Darby canine kidney cells in the manufacture of live attenuated influenza virus vaccines. In November 2005 the panel held a meeting on the use of Madin-Darby cells for manufacture of inactivated flu vaccine.